The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...
TCT 62: Long-Term Outcomes of Patients at Both High Ischemic and Bleeding Risk (Bi-Risk) on Clopidogrel-Based Dual Antiplatelet Therapy, Insights from the UF-GENOTYPE Registry. Receive the the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results